Health-care companies fell as traders retreated from high-risk corners of the market such as biotechnology and obesity-drug makers.
The iShares Biotech exchange-traded fund, a basket of major biotech firms, slipped by 0.9%, but remains near all-time highs. Merger activity and breakthroughs in oncology have reinvigorated investor enthusiasm for the sub sector in recent weeks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.